Newsmeme!
Discover News you didn't know existed

• home
• news
• tagging
• how it works
• about
• data

Gene Therapy

News

First Ever In-vivo Efficacy Data For A MicroRNA Therapeutic Disease Model

Published December 1, 2008, 12:10 pm, Medical News Today

Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication of new research in the journal Nature on the role of a microRNA, known as miR-21, in heart failure(1).

Full Story

Tags

No tags found at this time. Be the first to tag this news item, learn more.

Imagery

Related Gene Therapy Stories

From Various News Sources

Regulus Therapeutics, Alnylam Pharmaceuticals, and Collaborators ... - PR Inside
www.regulusrx.com - Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced ...

Regulus Therapeutics, Alnylam Pharmaceuticals, and Collaborators - MSN MoneyCentral
Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. ALNY and Isis Pharmaceuticals, Inc. ISIS formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication of new research in ...

Rodman & Renshaw Annual Global Investment Conference Presenter ... - TMCnet
NEW YORK --(Business Wire)-- The Rodman & Renshaw Annual Global Investment Conference takes place November 10, 2008 - November 12, 2008 at the New York Palace Hotel in New York. Listed below are the Rodman & Renshaw Annual Global Investment ...

Related Social Bookmarks

None found at this time.